Dynamic Technology Lab Private Ltd Buys 32,104 Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX)

Dynamic Technology Lab Private Ltd grew its stake in GoodRx Holdings, Inc. (NASDAQ:GDRX) by 260.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 44,419 shares of the company’s stock after buying an additional 32,104 shares during the period. Dynamic Technology Lab Private Ltd’s holdings in GoodRx were worth $308,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in GDRX. nVerses Capital LLC acquired a new stake in GoodRx during the 3rd quarter valued at approximately $33,000. Plato Investment Management Ltd bought a new stake in shares of GoodRx in the 2nd quarter valued at $43,000. Dark Forest Capital Management LP acquired a new stake in shares of GoodRx during the second quarter worth $86,000. Quest Partners LLC bought a new position in GoodRx during the third quarter worth $160,000. Finally, Deerfield Management Company L.P. Series C acquired a new position in GoodRx in the second quarter valued at $173,000. 63.77% of the stock is currently owned by institutional investors.

Insider Activity at GoodRx

In related news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the business’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $7.86, for a total transaction of $83,921.22. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 4.17% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the company. Citigroup decreased their price target on GoodRx from $10.00 to $7.00 and set a “buy” rating for the company in a report on Wednesday, November 13th. Royal Bank of Canada reiterated an “outperform” rating and issued a $10.00 target price on shares of GoodRx in a report on Friday, August 16th. Raymond James raised GoodRx from an “outperform” rating to a “strong-buy” rating and set a $10.00 price target on the stock in a research note on Friday, August 9th. Barclays reduced their price objective on shares of GoodRx from $10.00 to $6.00 and set an “overweight” rating for the company in a research report on Monday, November 11th. Finally, UBS Group dropped their target price on shares of GoodRx from $9.00 to $8.50 and set a “neutral” rating on the stock in a research report on Friday, August 9th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $8.86.

GoodRx Price Performance

GDRX stock opened at $4.84 on Monday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 5.48 and a current ratio of 5.48. The business has a 50-day simple moving average of $5.98 and a two-hundred day simple moving average of $7.25. The company has a market capitalization of $1.84 billion, a P/E ratio of -161.33, a price-to-earnings-growth ratio of 3.52 and a beta of 1.39. GoodRx Holdings, Inc. has a 52-week low of $4.09 and a 52-week high of $9.26.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.